Nine (Amato et al. 2014; Chadwick et al. 2009; Fritz et al. 2009; Hosoda et al. 2015; Kuboki et al. 2015; Lubezky et al. 2011; Schönleben et al. 2008; Singhi et al. 2014; Wu et al. 2011b) and seven (Amato et al. 2014; Hosoda et al. 2015; Ideno et al. 2015; Kanda et al. 2013; Kuboki et al. 2015; Singhi et al. 2014; Wu et al. 2011b) studies presented KRAS and GNAS mutations of IPMN patients, according to the histologic grades. Here, GNAS is linked to pancreatic intraductal papillary-mucinous neoplasm.